• January 25, 2006

    Adelphia Targets Its Former Law Firm For Investigation

    Bankrupt cable television provider Adelphia Communications Corp. has turned up the heat on its former law firm after deciding Tuesday to launch an investigation into its attorneys' alleged conflict of interest.

  • January 24, 2006

    Judge Denies Ex-Gemstar Exec Plea Bargain

    Former Gemstar CEO Henry Yuen’s plea bargain, which raised cries of protest for its relative leniency, has been denied by a judge, sending the executive and federal prosecutors back to the bargaining table.

  • January 23, 2006

    Ameriquest To Pay $325M Over Fraud Charges

    Ameriquest Mortgage Co., the largest privately held mortgage firm in the United States, has agreed to pay $325 million to settle one of the most widespread cases of predatory lending in the country’s history.

  • January 20, 2006

    AOL Latin America Offers Creditors Deal

    Shareholders of America Online’s bankrupt Latin American division have proposed a liquidation plan that will allow unsecured creditors to recover 100% of their claims, but only if they agree not to hold them liable for the Internet unit’s collapse.

  • January 17, 2006

    Winn Dixie Equity Committee Disbanded

    Shareholders of grocery store chain Winn-Dixie will no longer have a say in the struggling company’s bankruptcy proceedings after a judge disbanded the equity committee in Winn-Dixie’s Chapter 11 case.

  • January 13, 2006

    NY Governor Candidate Implicated In School Bankruptcy

    A now-defunct Kentucky college that owes over $3 million in loans taken out by its former chief executive should not be liquidated, according to a Kentucky bank, because the sale of all the school’s assets would still not be enough to pay back the borrowed money.

  • January 11, 2006

    SEC Eyes Hedge Fund's Influence In Merger Talks

    Continuing its probe of the lightly-regulated hedge fund industry, the Securities and Exchange Commission is eyeing investment manager Perry Capital LLC regarding questionable trading techniques that allowed the firm to influence a pharmaceutical company’s takeover plans.

  • January 11, 2006

    SEC Probes Drug Trial Firm Accused Of Recklessness

    The problems facing drug-testing firm SFBC International expanded this week when the Securities and Exchange Commission issued an informal request for documents related to two executives who recently left the company.

  • January 11, 2006

    Toyota Slapped With ITC Complaint By Engine Maker

    A tiny electric engine maker filed a complaint Wednesday with the U.S. International Trade Commission against auto giant Toyota for infringing on its patented hybrid car technology. The action comes just four months after another suit was filed against Toyota by Solomon in a Florida District Court, which has been stalled due to troubles financing the litigation.

  • January 5, 2006

    Damages In Little-Known Biotech Suit Reach Record Level

    In the epilogue to an acrimonious battle over a drug that could be worth billions of dollars, a federal jury has ordered a California biotechnology company to pay an additional $30 million in punitive damages to a small family-owned pharmaceutical company whose patents it illegally licensed.

  • January 4, 2006

    European Union Buckles To U.S. On Regional Brands

    The European Union has caved in under pressure from the U.S. and Australia to simplify its registration procedure for foreign agricultural products after a protracted food fight over geographic indications.

  • January 1, 2006

    SEC Chastizes Ex-Gemstar Exec Plea Bargain

    The U.S. Securities and Exchange Commission has openly criticized the Justice Department’s plea agreement with former Gemstar CEO Henry Yuen, telling a judge that prosecutors may have been too lenient in settling with the embattled executive.

  • December 21, 2005

    Tiny Biotech Company Wins $48M Trade Secret Award

    After a six-year feud over a potential blockbuster drug, a small family-owned pharmaceutical company has been awarded $48 million from a biotechnology firm accused of illegally licensing its patents.

  • December 20, 2005

    Judge Calls Ex-Gemstar CEO’s Sentence Too Lenient

    A judge has delayed the sentencing of former Gemstar CEO Henry Yuen, saying that the penalty agreed to in the plea bargain is too lenient for the former executive, accused of aiding in a $248 million fraud.

  • December 20, 2005

    Andrx, Glaxo In New Row Over Wellbutrin

    Extending the drawn-out legal row over generic Wellbutrin, a subsidiary of Andrx Pharmaceuticals LLC has sued British rival GlaxoSmithKline PLC, alleging the company’s current formula for the antidepressant infringes Andrx’s patent.

  • December 15, 2005

    J&J Cries Trademark Breach Over Reprocessed Devices

    Johnson & Johnson subsidiary Ethicon Endo-Surgery has accused a rival of reprocessing its single-use surgical scalpels and reselling them to hospitals without removing the Ethicon service mark, thereby infringing the company’s trademark.

  • December 15, 2005

    Morrison & Foerster's Asian Connection Pays Off

    Morrison & Foerster LLP, a powerhouse in securities litigation in the United States, traces much of its success to the firm's extensive presence in Asia.

  • December 12, 2005

    Morgan Stanley Appeals $1.5B Perelman Verdict

    Morgan Stanley has appealed the $1.45 billion award won by financier Ronald Perelman earlier this year in a dispute over Perelman’s sale of camping-gear company to Sunbeam Corp. in 1998.

  • December 6, 2005

    J&J Medical Device Prevails In Trade Secret Appeal

    A Johnson & Johnson medical device prevailed in the U.S. Court of Appeals for the Sixth Circuit when the doctor that sued the company for trade secret violations failed to show proper similarity between his heart surgery device and J&J’s alleged copy.

  • December 2, 2005

    SEC In $25M Settlement Over Life Insurance Fraud

    The Securities and Exchange Commission has reached a $25 million settlement with a company it probed for allegedly defrauding thousands of terminally ill patients by manipulating their life insurance policies.